Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994279 | 0.93 | PTPN11 (0.51) | PTPN11PTPN1PTPN6 | |
| SCHEMBL4829715 | 0.93 | PTPN11 (0.51) | PTPN11PTPN1PTPN6 | |
| SCHEMBL3995245 | 0.91 | CNR2 (0.46) | HDAC1HDAC6CNR2PTPN11PTPN1 | |
| SCHEMBL8334699 | 0.89 | PTPN11 (0.48) | HDAC1HDAC6CNR2PTPN11PTPN1 | |
| SCHEMBL5926927 | 0.87 | HDAC1 (0.48) | HDAC1HDAC6CNR2ABCG2 | |
| SCHEMBL5926212 | 0.87 | ABCG2 (0.62) | HDAC1HDAC6ABCG2 | |
| SCHEMBL4827793 | 0.87 | ABCG2 (0.62) | HDAC1HDAC6ABCG2 | |
| SCHEMBL4827796 | 0.87 | ABCG2 (0.62) | HDAC1HDAC6ABCG2 | |
| SCHEMBL5926426 | 0.86 | HDAC1 (0.46) | HDAC1HDAC6CNR2ABCG2 | |
| SCHEMBL3993038 | 0.86 | HDAC1 (0.51) | HDAC1HDAC6CNR2ABCG2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | HDAC1 656/4885HDAC6 518/4885CNR2 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.